BioNTech's Oncology Pipeline Delivers as Vaccine Headwinds Persist

BioNTech shares closed at EUR 83.80 as investors weigh Gotistobart's Phase 3 survival data against a BMO downgrade on weak COVID vaccine demand.

BioNTech's share price tells a story of two companies pulling in opposite directions. On Friday, the Mainz-based biotech closed at EUR 83.80 on Xetra, down 2.6% — a muted reaction to news that would ordinarily lift a vaccine maker's stock: U.S. regulators had just cleared the company's XFG-targeted shot, developed with partner Pfizer, for the upcoming immunization season.

That the approval landed with barely a ripple says much about where investor attention now sits. The market has grown accustomed to a shrinking COVID franchise, and the regulatory green light, while welcome, does little to change the near-term revenue picture. What is drawing scrutiny instead is the company's clinical pipeline — and there, the news has been considerably more compelling.

Gotistobart Posts Landmark Survival Data

Updated results from the Phase 3 PRESERVE-003 trial, released on September 14 in partnership with OncoC4, showed the antibody Gotistobart achieving a median overall survival of 18.5 months in patients with pretreated squamous non-small cell lung cancer. The standard chemotherapy comparator, docetaxel, managed just 10.0 months. The data cutoff was July 17, 2026, with a hazard ratio of 0.56.

Reuters characterized the findings as demonstrating a clinically meaningful survival benefit — one that emerged in patients whose tumors had progressed despite prior immunotherapy and chemotherapy. Nearly doubling survival in that advanced, heavily pretreated population is a striking result, particularly given how limited therapeutic options have traditionally been for this group.

For BioNTech, the readout offers tangible evidence that its pivot toward oncology is producing results rather than just promises. The company has spent years signaling its intent to move beyond pandemic-era vaccine revenues, and Gotistobart represents the clearest validation yet of that strategy.

Analysts Trim Targets on Vaccine Weakness

The enthusiasm around the cancer pipeline has not been enough to offset deteriorating sentiment on the vaccine side. BMO Capital Markets downgraded the stock on September 8 from Outperform to Market Perform, cutting its price target to $105 from $128. The analysts cited softening global demand for COVID vaccines and inventory destocking in Germany as the primary drivers.

Those concerns are difficult to dispute. The extraordinary conditions that drove pandemic-era sales have fully unwound, and the company's legacy vaccine business is now navigating a far more ordinary demand environment. Still, the downgrade reflects a backward-looking view of the business, one that assigns little value to the clinical assets now maturing in the pipeline.

A Stock Caught Between Two Narratives

The tension between these two stories shapes BioNTech's current valuation. Shares remain 21% below their 52-week high, yet the stock has managed a modest 3.0% gain since the start of the year — a reflection of investors weighing near-term vaccine headwinds against longer-term oncology potential.

That hesitation is characteristic of the biotechnology sector, where late-stage trials demand substantial capital and carry inherent development risk. Before committing to a sustained re-rating, shareholders understandably want durable proof of future market access.

BioNTech's solid liquidity position gives management room to navigate lengthy regulatory reviews without financial strain. If the company can stack additional robust Phase 3 datasets behind Gotistobart, the case for a gradual reassessment of the stock becomes considerably stronger. For now, the market appears content to wait — watching the science advance while the vaccine business finds its new normal.